Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
106.9 USD | -0.55% | -0.07% | -2.79% |
04:21pm | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
04-26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-2.79% | 187B | |
-2.00% | 106B | |
-4.45% | 66.9B | |
+0.73% | 49.45B | |
+16.63% | 48B | |
+4.06% | 40.84B | |
+3.61% | 26.48B | |
+1.03% | 26.25B | |
+12.96% | 24.62B | |
-0.25% | 24.52B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Abbott Raises 2022 Outlook on Improved Second-Quarter But Revenue Excluding COVID-19 Test Sales Take Recall Hit